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Cysteine proteases are involved in many physiological processes and their hyperac-
tivity may lead to severe diseases. Nature has developed various strategies to protect
cells and whole organisms against undesired proteolysis. One of them is the control
of proteolytic activity by inhibition. This paper presents the mechanisms underlying
the action of proteinaceous inhibitors of cysteine proteinases and covers propeptides
binding backwards relative to the substrate or distorting the protease catalytic cen-
tre similarly to serpins, the p35 protein binding covalently to the enzyme, and
cystatins that are exosite binding inhibitors. The paper also discusses tyropins and
chagasins that, although unrelated to cystatins, inhibit cysteine proteinases by a sim-
ilar mechanism, as well as inhibitors of the apoptosis protein family that bind in a di-
rection opposite to that of the substrate, similarly to profragments. Special attention
is given to staphostatins, a novel family of inhibitors acting in an unusual manner.
Proteolytic enzymes catalyse the hydrolytic
cleavage of peptide bonds. They can be classi-
fied as exopeptidases and endopeptidases
(proteinases) that are further subdivided into
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serine-, aspartic-, metallo- and cysteine pro-
teinases (Barrett et al., 1998). The latter have
been found in viruses and prokaryotes as well
as in higher organisms such as plants and
mammals, including humans. Mammalian
cysteine proteinases fall into two classes:
caspases (Chapman et al., 1997; Barrett et al.,
1998) and the papain superfamily comprising
the papain family, calpains and bleomycin hy-
drolases (Otto & Schirmeister, 1997; Barrett
et al., 1998; McGrath et al., 1999).
Cysteine proteinases participate in varied
biological processes. The cathepsins alone are
involved in protein breakdown in lysosomes,
antigen presentation, proteolytic processing
of proenzymes and prohormones, fertiliza-
tion, cell proliferation, differentiation and
apoptosis (Chapman et al., 1997;
Grzelakowska-Sztabert, 1998; Berdowska &
Siewiński, 2000). Imbalanced activity of en-
dogenous cysteine proteinases may lead to
numerous pathologies such as rheumatoid ar-
thritis, multiple sclerosis, neurological disor-
ders, tumours and osteoporosis (Berdowska
& Siewiński, 2000). The cysteine proteinases
produced by pathogenic bacteria are consid-
ered important virulence factors and their
role in the development of many diseases, e.g.
in paradontosis, is postulated (Takahashi et
al., 1994; 1999; Pavloff et al., 1995; Potempa
et al., 1995; Lowy et al., 1998; Takeuchi et al.,
1999; Rice et al., 2001; Dubin, 2002; 2003).
Thus, precise control of proteolytic pro-
cesses is essential for appropriate functioning
of cells and whole organisms. This is achieved
at many levels, from regulation of protease
expression, secretion and maturation,
through specific degradation of mature en-
zymes, to blockage of their activity by inhibi-
tion. Due to possible applications of selective
proteinase inhibitors in therapy, the mecha-
nisms underlying inhibition are being thor-
oughly investigated. This paper reviews the
inhibitory mechanisms employed to control
the activity of one particular class of pro-




Before characterizing modes of their inhibi-
tion, let us explain the catalytic mechanism of
cysteine proteases themselves. The proteases
of this group are most commonly exemplified
by papain, a well described plant enzyme iso-
lated from the latex of Carica papaya fruit.
The papain molecule consists of two
subdomains forming the active site cleft of
the enzyme (Mitchell et al., 1970; Drenth et
al., 1976; Garavito et al., 1977; Kamphuis et
al., 1984; Varughese et al., 1989).
The proteolytic activity of all cysteine pro-
teases arises from the presence of the cata-
lytic Cys and His residues in the enzyme ac-
tive centre. In the case of papain-like cysteine
proteinases, the catalytic centre is comple-
mented with Asn that ensures an orientation
of the His imidazole ring optimal for succes-
sive stages of hydrolysis.
The crucial step of the catalytic process in-
volves formation of a reactive thiolate/imi-
dazolium ion pair (Cys-S–/His-Im+), which re-
sults from proton transfer between Cys-25
and His-159 (papain numbering).
In principle, the thiolate anion attacks the
carbonyl carbon of the scissile peptide bond,
and the double bond between the carbon and
the oxygen converts into a single one
(Fig. 1A). The oxygen assumes a negative net
charge allowing formation of the first tetrahe-
dral transition state. The oxyanion is stabi-
lized by hydrogen bonding to the NH groups
of Gln-19 side chain and Cys-25 backbone,
which is likely to result in the formation of an
oxyanion hole (Fig. 1B) (Menard et al., 1991;
Menard et al., 1995; Harrison et al., 1997;
Otto & Schirmeister, 1997). Subsequent rota-
tion of the His residue enables proton trans-
fer from the imidazolium cation to the nitro-
gen of the peptide bond being hydrolyzed, and
cleavage occurs. The newly formed substrate
amine is hydrogen bonded to His-159,
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whereas the substrate carboxylic part is
linked to Cys-25 via a thioester bond, forming
acyl enzyme (Fig. 1C). The next reaction step
involves dissociation of the aminic part of the
substrate and its replacement with a water
molecule. The imidazole nitrogen contributes
to polarization of the water molecule that in
turn attacks the carbonyl carbon of acyl en-
zyme (Fig. 1D). This is followed by formation
of the second tetrahedral intermediate
(Fig. 1E). In the final step, thioester
deacylation leads to reconstruction of the car-
boxyl group in the hydrolyzed substrate,
which is concerted with the release of an ac-
tive enzyme (Fig. 1F) (Menard et al., 1991;
Otto & Schirmeister, 1997).
PROPEPTIDES — THE BACKWARD
BINDING
A considerable number of cysteine protein-
ases are synthesized as inactive precursors.
Their activation requires proteolytic cleavage
of the N-terminal proregion that also func-
tions as inhibitor of the mature enzyme
(Groves et al., 1998). Crystallographic studies
of procathepsins B, L and K shed light on the
propeptide inhibitory mechanism (Fig. 3A)
(Turk et al., 1996; Fujishima et al., 1997;
Podobnik et al., 1997; LaLonde et al., 1999;
Wiederanders, 2003; Wiederanders et al.,
2003).
The majority of cysteine protease pro-
fragments share similar fold and consist of
two parts. The profragment N-terminal por-
tion is built up of two -helices and an ex-
tended -strand, and interacts with a sur-
face-localised “proregion binding loop” of the
mature protease. The C-terminal segment
binds between the two domains of the en-
zyme, being anchored at the S’ sites
(Schechter and Berger nomenclature, see
Fig. 2) by a short -helix. Its backbone covers
the substrate binding site, which hinders ac-
cess to the enzyme’s catalytic centre. How-
ever, the binding modes of the substrate and
the propeptide are opposite in direction. Al-
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Figure 1. Catalytic mechanism of cysteine proteinases as exemplified by papain (description in the
text).
though the propeptide sidechains utilise the
same binding sites as the substrates, the re-
verse orientation of the polypeptide chain re-
sults in such a position of the peptide bond
that makes it resistant to cleavage (Fox et al.,
1992; Carmona et al., 1996; Coulombe et al.,
1996; Cygler & Mort, 1997; Podobnik et al.,
1997; Wiederanders et al., 2003).
pSpeB — PROFRAGMENT THAT
DISTORTS THE ENZYME CATALYTIC
CENTRE
An unusual mechanism of proregion inhibi-
tion has been described for streptococcal
pyrogenic exotoxin B (SpeB), a papain-like
protease isolated from Streptococcus pyogenes
(Fig. 3B). The structure of the SpeB pro-
fragment portion (pSpeB) is unique, compris-
ing a four-stranded antiparallel -sheet
flanked by two -helices. Despite the fact that
pSpeB binds the enzyme surface in a position
that corresponds to the localisation of the
‘proregion binding loop’ in procathepsins, its
mode of interaction with the protease active
site cleft is substantially different (Kagawa et
al., 2000). The crystal structure of SpeB
zymogen revealed that the predominant inter-
actions with the active site of the mature en-
zyme are mediated by the first turn of one of
the propeptide -helices. The most crucial in
SpeB inhibition is the Asn-89 residue that
penetrates the substrate binding groove of
the mature enzyme in a position analogous to
the S1’ site of other papain-like proteases.
This results in the catalytic His-195 being
pushed out from the active centre, preventing
any interactions with the catalytic Cys-47 res-
idue. Consequently, the protease reactive site
is distorted and SpeB has no catalytic potency





Enzyme inactivation through active site dis-
tortion is adopted by other inhibitors as well.
Recently, it has been shown that some
serpins (serine protease inhibitors) are capa-
ble of blocking the activity of both serine and
cysteine proteinases. Such inhibitors are usu-
ally exemplified by squamous cell carcinoma
antigen 1 (SCCA1) targeting the papain-like
cathepsins S, K and L (Schick et al., 1998a;
1998b), and the cowpox virus-encoded cyto-
kine response modifier A (CrmA) that selec-
tively inhibits caspases 1 and 8 as well as the
serine protease granzyme B (Zhou &
Salvesen, 2000; Stennicke et al., 2002).
The crystal structures of complexes between
CrmA or SCCA1 and proteases have not been
determined so far. The characteristic struc-
tural feature of all serpin superfamily mem-
bers is the presence of a surface exposed reac-
tive site loop that functions as a target for
proteases. Since the loop has been found cru-
cial for the inhibitory activity of both CrmA
and SCCA1 (Schick et al., 1998a), it is as-
sumed that serpins inhibit both serine and
cysteine proteinases in a similar manner.
An insight into the inhibitory mechanism of
serpins was provided by the crystal structure
of a complex between trypsin, a serine prote-
ase, and antitrypsin that belongs to serpins
(Huntington et al., 2000). In general, upon in-
teracting with trypsin, the reactive site loop
of antitrypsin is cleaved, whereas the cata-
lytic Ser of the enzyme and the carbonyl car-
bon of the inhibitor P1 residue form an ester
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Figure 2.: Schechter and Berger nomenclature.
S4–S3’ — substrate binding sites within the active site
of the enzyme, P4–P3’ — substrate residues that bind
to S4–S3’ sites, arrow indicates the scissile bond
(Schechter & Berger, 1967).
bond. The newly formed N-terminal part of
the loop, covalently linked to the protease, re-
locates and becomes incorporated into the
body of the antitrypsin molecule, which alters
the position of the enzyme relative to the in-
hibitor. This leads to partial denaturation of
the protease molecule and disruption of its
catalytic centre (Huntington et al., 2000). Due
to the enzyme’s inability to conduct further
catalysis, the acyl intermediate, identical to
that observed during substrate hydrolysis, is
stabilized and the protease becomes inactive
(Stennicke et al., 2002).
Several lines of evidence, e.g. the crystal
structure of free CrmA and some biochemical
data, suggest that the interaction with
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Figure 3. Ribbon drawing of inhibitory complexes formed by A, procathepsin L (PDB code: 1cs8); B,
SpeB zymogen (1dki); C, p35 and caspase 8 (1i4e); D, stefin B and papain (1stf); E, p41 and cathepsin L
(1icf); F, XIAP and caspase 3 (1i3o); G, staphostatin B and staphopain B (1pxv).
Inhibitors are shown in blue, enzymes in red. The location of the catalytic Cys and His residues is shown in green,
regions of inhibitor that are most important for interaction with enzyme are labelled yellow. Figure made with
WebLabProViewer.
caspase results in the cleavage of the peptide
bond within the substrate-like reactive site
loop of CrmA. Upon cleavage, the inhibitor
undergoes a conformational change into a
more stable form rendering the whole process
practically irreversible (Stennicke et al.,
2002). In the case of caspase inhibition by
CrmA, it is supposed that the enzyme cata-
lytic Cys residue links to the inhibitor via a
thioester bond. The CrmA reactive site loop is
shorter than in most serpins, which provides
a basis for the assumption that the caspase
catalytic Cys, while covalently bound to
CrmA, is in a position corresponding to that
of the catalytic Ser in the complexes of other
serpins with their target serine proteases.
Likewise, this might allow deformation of the
caspase structure (Simonovic et al., 2000; Ye
& Goldsmith, 2001), although in such a case
partial denaturation would presumably lead
to dissociation of the protease into two sub-
units (Stennicke et al., 2002).
However, the cross-class serpins seem to dif-
fer from other members of the serpin
superfamily by their inability to form stable
covalent complexes with target cysteine pro-
teinases (Simonovic et al., 2000; Masumoto et
al., 2003). Recently, two ways of papain inhi-
bition by SCCA1 have been suggested that
comprise the suicide substrate-like mecha-
nism without formation of a covalent com-
plex, and irreversible impairment of papain
catalytic activity by disruption of the en-
zyme’s structure (Masumoto et al., 2003).
Nevertheless, the proposed scheme of inter-
action between serpins and cysteine proteas-
es will be ultimately confirmed upon determi-
nation of the structure of at least one
serpin–protease complex.
p35 — COVALENT INHIBITION AND
STERIC HINDRANCE
The p35 protein is another example of
cysteine protease covalent inhibitors. It is
produced by baculoviruses in the early phase
of infection in order to suppress the host im-
mune response. The members of the p35 pro-
tein family have an ability to inhibit almost all
known caspases and usually do not exhibit
any activity towards the enzymes of other
protease families (Stennicke et al., 2002). The
structure of free p35 protein consists of four
-helices, a central -sheet and a reactive site
loop exposed over the surface (Fig. 3C) (Ye &
Goldsmith, 2001). Based on the structure of
human caspase 8 complexed with baculovirus
p35 protein, it was discovered that the en-
zyme inactivation results from the formation
of a covalent thioester bond between the
caspase 8 catalytic Cys-360 residue and the
P1 Asp-87 residue localized within the sub-
strate-like reactive site loop of the inhibitor.
Following cleavage of the reactive site loop,
the p35 protein undergoes a number of
conformational changes that result in the in-
sertion of its N-terminal portion into the en-
zyme active site cleft. Consequently, the
caspase catalytic His-317 residue is inaccessi-
ble for solvent molecules, which prevents hy-
drolysis of the thioester bond. Presumably, at
the same time a hydrogen bond is formed be-
tween the His-317 catalytic residue and the
Cys-2 thiol group of the p35 N-terminus,
which leads to an unfavourable rotation of the
His-317 imidazole ring and arrests catalysis
(Xu et al., 2001).
The p35 protein is distinct from serpins in
the mechanism of enzyme inactivation (Xu et
al., 2001; Ye & Goldsmith, 2001). The serpins
distort the enzyme catalytic centre and rear-
range the protease molecule, whereas in the
caspase–p35 protein complex the proteolysis
is blocked directly by the inhibitor, due to
conformational changes within its molecule
(Xu et al., 2001).
CYSTATINS — EXOSITE BINDING
INHIBITORS
Cystatins constitute the largest and best de-
scribed group of natural cysteine proteinase
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inhibitors (Bode et al., 1990). They are di-
rected against the papain superfamily mem-
bers found in viruses, bacteria, plants and an-
imals. On the basis of sequence homology, the
cystatin superfamily is divided into three
groups: stefins (family I), cystatins (family II)
and kininogens (family III) (Otto & Schir-
meister, 1997; Barrett et al., 1998; Grzonka et
al., 2001).
The mechanism of cystatin action was eluci-
dated by numerous kinetic and crystallo-
graphic studies (Fig. 3D) (Abrahamson et al.,
1987; Abrahamson, 1988; Bode et al., 1988;
Hall et al., 1995; Masson et al., 1998; Stubbs et
al., 1990). Cystatins are exosite binding inhib-
itors and they bind adjacent to the protease
active site, obstructing the access of sub-
strate, but do not interact with the enzyme
catalytic centre directly (Bode & Huber,
2000).
Determination of chicken egg white cystatin
structure revealed that the cystatin inhibitory
domains are composed of five antiparallel
-strands wrapped around a central -helix.
The molecule scaffold takes the shape of a
wedge that fits into the substrate binding
groove of papain. The wedge’s edge is formed
by the partially flexible N-terminus contain-
ing the characteristic Gly-8 and Ala-10 resi-
dues and two hairpin loops carrying highly
conservative motifs QVVAG and PW (Bjork &
Ylinenjarvi 1989; Hall et al., 1993; 1995;
Grzonka et al., 2001).
The three-dimensional structure of the com-
plex formed between human stefin B and
papain conveyed the full understanding of
cystatin inhibitory mechanism. The two hair-
pin loops, typical for cystatins, interact with
the enzyme surface at the S1’ through S4’
binding sites, whereas the N-terminal portion
of the cystatin molecule runs through the
S3–S1 subsites. Although the polypeptide
chain binds in a substrate-like manner, at the
P1 position it points away from the enzyme
active site and so avoids cleavage. The
cystatin molecule remains intact, but still pre-
vents interactions with substrates, being
non-productively bound to the enzyme
(Stubbs et al., 1990).
THYROPINS AND CHAGASINS —
‘CYSTATIN-LIKE’ INHIBITION
The very efficient mechanism of inhibition
observed in cystatins was also described for
inhibitors that belong to protein families not
only unrelated to cystatins, but also of an en-
tirely different fold.
The first group of such proteins is formed by
thyropins, the protease inhibitors whose
structures contain an arrangement desig-
nated as thyroglobulin type-1 domain (Lenar-
cic et al., 1999). Crystallographic analyses of
major histocompatibility complex class II-as-
sociated p41 invariant chain bound to
cathepsin L provided the molecular back-
ground for the mechanism of interaction be-
tween thyropins and their target proteases
(Fig. 3E) (Guncar et al., 1999). The p41 frag-
ment consists of two subdomains: the first
one composed of an -helix and a -strand,
the second subdomain being a three-stranded
antiparallel -sheet. Similarly to cystatins,
the molecule is wedge-shaped and interacts
with the enzyme through three hairpin loops
(Guncar et al., 1999). However, the different
overall structure results in additional con-
tacts with the surface of the protease, deter-
mining high specificity of thyropins and dis-
tinguishing them from the relatively non-se-
lective cystatins (Guncar et al., 1999; Bode &
Huber, 2000).
The chagasin family members presumably
share a comparable mode of inhibition. Cha-
gasins were first identified in Trypanosoma
cruzi and they are inhibitory towards
papain-like proteinases of bacterial, proto-
zoan and mammalian origin (Monteiro et al.,
2001; Rigden et al., 2002; Sandersen et al.,
2003). Although the three-dimensional struc-
ture of any chagasin is so far unknown, com-
puter based predictions revealed that it
should have an immunoglobulin-like fold and
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contain a sequence motif corresponding to
two adjacent -strands connected via a short
turn. This suggests a wedge-like structure re-
sembling that inserted into the papain and
cathepsin L active sites by stefin B and p41
(Monteiro et al., 2001; Rigden et al., 2002;
Sandersen et al., 2003).
IAP — PROTEINACEOUS INHIBITORS
THAT BIND BACKWARDS
The next noteworthy group of cysteine pro-
tease inhibitors comprises inhibitors of the
apoptosis protein family (IAP), endogenous
proteins that function through direct inhibi-
tion of caspases. Their most distinguishable
characteristic is the subunit structure with
one or more BIR (baculovirus IAP repeat)
domains.
On the basis of the three-dimensional struc-
tures of complexes between human XIAP
BIR2 domain and caspases 3 or 7 it has been
established that the BIR domain does not
contribute directly to the protease inhibi-
tion, whereas all prominent contacts are me-
diated through the flexible portion of the
XIAP polypeptide chain preceding the BIR
domain. This portion consists of the regions
designated ‘hook’, ‘line’ and ‘sinker’, and
proceeds along the enzyme active site cleft in
a direction opposite to that of substrates
(Fig. 3F).
The mechanism of caspase 3 and 7 inhibi-
tion is based on sterically hindering the sub-
strate access to the enzyme catalytic centre,
mostly via non-covalent interactions of the he-
lical ‘hook’ with the outer edge of the sub-
strate canyon, while the BIR domain and the
‘sinker’ region are responsible for stabiliza-
tion of the inhibitory complex (Chai et al.,
2001; Riedl et al., 2001; Stennicke et al.,
2002). However, the most remarkable and
unique feature of the mode of caspase 3 and 7
inhibition by XIAP is the backward binding
accompanied by the lack of interactions
within the S1 substrate binding site.
STAPHOSTATINS — A NEW FAMILY
OF INHIBITORS
Recently, a new mechanistic class of
cysteine proteinases inhibitors has been iden-
tified. They were named staphostatins due to
their high specificity towards staphopains,
bacterial papain-like cysteine proteases (Rice
et al., 2001; Massimi et al., 2002; Rzychon et
al., 2003a). The staphostatins were found to
be -barrels formed by a three-stranded
mixed -sheet and a five-stranded anti-paral-
lel -sheet (Dubin et al., 2003; Rzychon et al.,
2003b).
The crystal structure of staphostatin B in
complex with staphopain B (Fig. 3G) revealed
that their most crucial interactions occur in
the region defined as the inhibitor binding
loop. The loop spans the protease active site
cleft in a direction analogous to that of sub-
strates (Filipek et al., 2003). An essential role
in the inhibitory mechanism is played by the
Gly-98 residue localized in the P1 position and
conserved in all staphostatins sequences. It
adopts an unusual, strained backbone confor-
mation that would be unavailable to any other
residue for steric reasons. This conformation
results in the O-C-S angle (made by the car-
bonyl oxygen and carbonyl carbon of the inhib-
itor P1–P1’ peptide bond, and sulphur of the
enzyme’s catalytic Cys) approaching 180, far
too high a value for effective nucleophilic at-
tack. Moreover, the position of the carbonyl ox-
ygen of the P1–P1’ peptide bond, relative to
the oxyanion hole-forming side chain NH of
Gln-19 and backbone NH of Cys-25, is distinct
from that anticipated for the substrate, which
prevents stabilization of the tetrahedral inter-
mediate. This blocks proteolysis in its initial
stage and renders the enzyme inactive (Dubin
et al., 2003; Filipek et al., 2003).
SUMMARY
All proteinaceous inhibitors of proteinases,
including cysteine proteinase inhibitors, act
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through steric blockage of the substrate ac-
cess to the enzyme catalytic centre. Nature
has developed a number of strategies to
achieve this goal (Fig. 4).
Most profragments follow the tactics of
spanning the enzyme active site in the direc-
tion opposite to that of substrates. Upon bind-
ing, the resulting peptide bond position pre-
vents hydrolysis of the proregion, as the
propeptide chain interposes a hindrance be-
tween the substrate and the catalytic centre
of the protease. A seemingly analogous inhibi-
tory mechanism is employed by proteins of
the IAP family that also occupy the enzyme’s
active site in a non-productive orientation.
An unusual mode of profragment inhibition
has been reported for pSpeB which distorts
the protease catalytic centre. Similarly, mem-
bers of the serpin superfamily inactivate tar-
get proteases by deformation of their active
sites. Moreover, they bind covalently and en-
force rearrangement of the entire enzyme
molecule.
The inhibitory mechanism utilized by
serpins as well as the p35 protein is com-
monly compared to a mousetrap. Inhibitor
(the trap) is initially treated as substrate but
in the course of reaction the transition state
gets stabilized and the enzyme (the mouse) is
trapped (Stennicke et al., 2002). However, un-
like serpins, the p35 protein does not reorga-
nize the protease structure but directly blocks
further proteolysis.
Three groups of structurally and evolu-
tionarily distinct protease inhibitors — cys-
tatins, thyropins and chagasins — adopt a
common strategy. They all bind adjacent to
the active centre and block the access of the
substrate indirectly, without engaging the en-
zyme’s catalytic residues.
Finally, yet another mechanism of action is
employed by staphostatins that bind directly
to the active site, still avoiding cleavage due
to the unusual conformation of the P1
residue.
The proteinaceous inhibitors of proteolytic
enzymes function as regulators of endoge-
nous proteases and contribute to protection
against the detrimental consequences of ex-
cessive exogenous protease activity. Detailed
understanding of the inhibitory mechanisms
they employ may provide prospects for treat-
ment of the diverse disorders that result from
defective control of proteolytic processes.
The authors gratefully acknowledge Prof.
Adam Dubin and Tomasz Dylag for critical
reading of the manuscript.
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Figure 4. Schematic representation of inhibitory
mechanisms directed against cysteine protein-
ases.
Inhibitors are shown in blue, enzymes in red, sub-
strate in green.
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